nigeria south africa asia pacificaustralia japan malaysia myanmar sri lanka europefrance germany ireland italy lithuania the netherlands poland romania spain united kingdom denmark finland hungary norway sweden north americacanada usa south americabrazil cisrussia ukraine affiliated websitestaro pharmaceutical industries limited dusa pharmaceuticals about usmilestones board of directors acquisitions & joint ventures awards & accreditations operationsresearch & development manufacturing quality responsibilitycsr ehs hiv aids anti malaria investorsfinancials annual reports & presentations annual report of subsidiary companies shareholder s information archives mediapress releases in the news media kit careerswork with us life sun pharma academic programmes home about milestones board of directors acquisitions & joint ventures awards & accreditations operations research & development manufacturing quality products formulations active pharmaceutical ingredients otc responsibility csr ranbaxy community healthcare society ranbaxy daiichi sankyo joint initiative ranbaxy science foundation ehs hiv aids anti malaria investors financials annual reports & presentation shareholder s information stock information dividend history unclaimed dividend statutory communications our policies and codes tools investors faqs archives sun pharma ranbaxy merger ranbaxy archives quarterly results annual reports corporate governance presentations share holding pattern unclaimed dividend media press releases in the news media kit careers work with us life sun pharma academic programmes business development contact global presence africa morocco nigeria south africa asia pacific australia malaysia myanmar sri lanka europe france germany ireland italy lithuania the netherlands poland romania spain united kingdom denmark finland norway north america canada usa south america brazil cis russia ukraine affiliated websites taro pharmaceutical industries limited dusa pharmaceuticals world s 5th largest speciality generic pharmaceutical company read about sun pharma we develop high quality affordable medicines trusted by healthcare professionals & patients in 150 countries across 5 continents read about our products our product offerings have the hallmark of technology based differentiation read about our r & d our multi cultural team of more than 30 000 employees is our most valuable asset read about our culture our passion for quality goes beyond business putting patients first is our motto read about our quality 45 manufacturingsites view our manufacturing sites 150 marketsserved explore our global operations 2000 marketedproducts explore our products 30 000 employees worldwide go to careers financial updates 29 aug fy17 q1 financial result transcript 12 aug fy17 q1 financial press release 12 feb fy16 q3 financial press release read more press releases 03 oct revital h woman launches healthy conversations initiative 01 oct sun pharma to announce late breaking results for tildrakizumab 06 sep sun pharma announces distribution alliance with mitsubishi tanabe pharma corporation in japan read more board of directors acquisitions & joint ventures awards & accreditations adverse event reporting research & development manufacturing products quality responsibility sun pharma ranbaxy merger ranbaxy archives annual reports investors relations media kit press releases sitemap employee portal vendors portal field staff portal sun pharma offers a program for individuals who want to disclose violations of us fda requirements related to facilities or products owned or operated by ranbaxy prior to sun pharma s acquisition of ranbaxy . if you wish to learn more about the program please click continue . copyright sun pharmaceutical industries ltd. privacy policy disclaimer twitter linkdin site credits